Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DpC
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DpC is an orally administered investigational drug currently in Phase 1 clinical development for the treatment of advanced solid tumors. The ongoing study aims to establish the maximum tolerated dose, evaluate its safety and tolerability, and explore its preliminary anti-tumor activity.
- Other names
- di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone hydrochloridedi2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone hydrochloridedi 2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone hydrochlorideDPC1-cyclohexyl-3-(dipyridin-2-ylmethylideneamino)-1-methylthiourea hydrochloride
02
Targets
NF-κBJNK (Mitogen-activated protein kinase kinase kinase family)
Beyond the preview
Go deeper on DpC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DpC.